Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 26;4(3):765-769.
doi: 10.1002/jha2.741. eCollection 2023 Aug.

CBFA2T3::GLIS2-positive acute leukemia with RAM and mixed T/megakaryocytic phenotype

Affiliations

CBFA2T3::GLIS2-positive acute leukemia with RAM and mixed T/megakaryocytic phenotype

Mahsa Khanlari et al. EJHaem. .

Abstract

Herein, we present a rare case of acute myeloid leukemia (AML) with CBFA2T3-rearrangement and the expression of megakaryocytic and lymphoid markers, highlighting the need for a high suspicion index in differential diagnosis and applying adequate workup to avoid misdiagnosing this entity. CBFA2T3::GLIS2-positive AML is primarily found in infants with non-down syndrome acute megakaryoblastic leukemia (non-DSAMKL). Flow cytometry immunophenotyping plays an important role in recognizing the unique immunophenotype of bright CD56 expression with dim/negative expression of HLA-DR, CD38, and CD45 termed the RAM immunophenotype in this entity. Still, CBFA2T3::GLIS2-positive acute leukemia with T/megakaryocytic markers could be misdiagnosed as T-lymphoblastic leukemia/lymphoma, early T-cell precursor acute lymphoblastic leukemia/lymphoma, NK lymphoblastic leukemia, AML with minimal differentiation, or AML with myelodysplasia-related changes.

Keywords: CBFA2T3; GLIS2; acute megakaryoblast leukemia; mixed phenotype acute leukemia.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Flow cytometry Immunophenotyping of the peripheral blood using an SSC/CD45 gating strategy, a CD45‐dim to negative blasts, 19% of total events (circled in SSA vs. CD45) are positive for cytoCD3 (partially bright), CD19 (dim), CD33, CD34, CD38 (dim), CD41 (dim), CD42b (partial, moderate), CD56 (bright), CD117, and CD123. Blasts are negative for CD1a, CD7, CD10, and HLA‐DR.
FIGURE 2
FIGURE 2
Histologic and immunohistochemical findings of bone marrow examination (aspirate smear and core biopsy) and right axillary lymph node. (A) The bone marrow aspirate smear shows small‐ to intermediate‐sized blasts with smooth open chromatin, small nucleoli, and a small amount of agranular basophilic cytoplasm (stain: Wright‐Giemsa; original magnification, ×1000), (B) The bone marrow biopsy is hypercellular with an increased number of blasts and foci of necrosis. Many eosinophils are seen in the inset image (stain: hematoxylin and eosin; original magnification, ×100 and ×600, respectively), (C) CD3(original magnification, ×400), (D) CD42b (original magnification, ×400), (E) lysozyme (original magnification, ×400), (F) cytochemical stain for myeloperoxidase is negative in blasts (arrowhead; original magnification, ×500), (G) Sections of the lymph node is entirely replaced by blasts. Mitotic figures and many scattered eosinophils are easily identified (stain: hematoxylin and eosin; original magnification, ×600), (H) CD42b (original magnification, ×400), and (I) CD56 (original magnification, ×400).

Similar articles

Cited by

References

    1. Gruber TA, Larson Gedman A, Zhang J, Koss CS, Marada S, Ta HQ, et al. An Inv(16)(p13.3q24.3)‐encoded CBFA2T3‐GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell. 2012;22(5):683–97. - PMC - PubMed
    1. Masetti R, Bertuccio SN, Pession A, Locatelli F. CBFA2T3‐GLIS2‐positive acute myeloid leukaemia. A peculiar paediatric entity. Br J Haematol. 2019;184(3):337–47. - PMC - PubMed
    1. Smith JL, Ries RE, Hylkema T, Alonzo TA, Gerbing RB, Santaguida MT, et al. Comprehensive transcriptome profiling of cryptic CBFA2T3‐GLIS2 fusion‐positive aml defines novel therapeutic options: a COG and TARGET pediatric AML study. Clin Cancer Res. 2020;26(3):726–37. - PMC - PubMed
    1. Thirant C, Ignacimouttou C, Lopez CK, Diop M, Le Mouel L, Thiollier C, et al. ETO2‐GLIS2 hijacks transcriptional complexes to drive cellular identity and self‐renewal in pediatric acute megakaryoblastic leukemia. Cancer Cell. 2017;31(3):452–65. - PubMed
    1. Le Q, Hadland B, Smith JL, Leonti A, Huang BJ, Ries R, et al. CBFA2T3‐GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target. J Clin Invest. 2022;132(22):e157101. - PMC - PubMed